Clinical Trial Update: Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 trial evaluating fractionated docetaxel in combination with radium-223 in metastatic castration-resistant prosta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Tufts Medical Center | Conditions: Metastatic Castrate Resistant Prostate Cancer | Phase 1 | Status: COMPLETED